Further to refinements in immunosuppression and the significant gains witnessed in outcomes over recent decades, liver transplantation has firmly established itself as the definitive treatment for end stage liver disease and selected instances of hepatic malignancy. However, there exists a constant divide between organ supply and demand, with the numbers of new entrants to liver transplant waiting lists consistently and significantly outstripping that of transplants performed annually, as exemplified by United Network for Organ Sharing (UNOS) data from the United States (1).